EMA Authorised: Jubbonti (denosumab) — Sandoz GmbH

View source ↗

Summary

EMA authorised Jubbonti, a denosumab product from Sandoz GmbH, for osteoporosis and postmenopausal osteoporosis, reflecting its use in reducing bone resorption.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Jubbonti (denosumab)

Snippet

Status: Authorised. Therapeutic area: Osteoporosis;Osteoporosis, Postmenopausal;Bone Resorption. MAH: Sandoz GmbH. Decision date: 27/11/2025